In a large Australian meta-analysis by Cho et al., evaluating 646 patients with ALM, patients who underwent anti-PD1 monotherapy had a significantly higher OS at 1-year compared to those who underwent anti-CTLA4 monotherapy (53% vs 34%, P<.001) (48). Here, CTLA4 is linked to acral lentiginous melanoma.